izalontamab brengitecan + almonertinib

izalontamab brengitecan + almonertinib is a combination therapy being investigated for the treatment of non-small cell lung cancer (NSCLC), specifically as a neoadjuvant treatment for patients with resectable stage II-IIIB EGFR-mutation positive disease. The regimen consists of izalontamab brengitecan (BL-B01D1), a first-in-class bispecific antibody-drug conjugate (ADC) targeting both EGFR and HER3, and almonertinib (aumolertinib), a third-generation EGFR tyrosine kinase inhibitor (TKI). Izalontamab brengitecan utilizes a bispecific antibody linked to a camptothecin-derivative payload (Ed-04), which acts as a topoisomerase I inhibitor, with a drug-to-antibody ratio of 8. Almonertinib provides targeted inhibition of EGFR-sensitizing and resistance mutations. This combination is currently being evaluated in a Phase II clinical trial sponsored by Sichuan University (West China Hospital) to assess its safety and efficacy in the neoadjuvant and adjuvant settings.

Other names

izalontamab brengitecan + aumolertinibBL-B01D1 + aumolertinib